Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSIL428
- Development stage
- Unknown
- Lead developer
- Wake Network
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
PSIL428 is a proprietary, naturally-derived microdose formulation of psilocybin developed by Wake Network. It is produced from natural fungi material and designed for use in clinical research as a potential treatment for depressive and anxiety disorders. Unlike synthetic formulations, PSIL428 emphasizes full-spectrum mushroom extract to provide consistent dosing and quality control. The drug has received a Certificate of Drug Registration from the Jamaican Ministry of Health & Wellness, making it one of the first legal natural psilocybin microdose products available globally for research purposes. Its mechanism of action is based on the modulation of serotonin receptors in the brain—primarily agonism at the 5-hydroxytryptamine receptor 2A (5-HT2A)—which is believed to underlie its psychoactive and therapeutic effects. Clinical trials are ongoing to assess its efficacy and safety in treating mental health conditions such as depression and anxiety[2][4].
- Brand names
- PSIL428PSIL-428PSIL 428
- Other names
- PSIL 428PSIL428PSIL-428naturally-derived microdosed psilocybin (Wake Network)
02
Targets
HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on PSIL428.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSIL428.